Gene Therapy – Market Outlook, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Gene Therapy Market Outlook

Thelansis’s “Gene Therapy Market Outlook, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gene Therapy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Gene Therapy Overview

Gene therapy is a cutting-edge medical approach that involves manipulating a person's genes to treat or even cure diseases. This revolutionary technique encompasses various mechanisms to achieve its objectives:

1. Replacing Faulty Genes: One approach is substituting disease-causing genes with healthy counterparts, effectively restoring normal gene function within the individual's cells.
2. Inactivating Dysfunctional Genes: Some gene therapies focus on deactivating genes malfunctioning or causing diseases, thereby mitigating their harmful effects.
3. Introducing Modified Genes: Another method involves introducing new or modified genes into the body to combat specific diseases or medical conditions.

Primarily confined to research laboratories, gene therapy is still experimental. However, it rapidly evolves into a viable therapeutic option and combines gene therapy with other treatments like immune modulation, chemotherapy, and radiotherapy. Gene therapy can be broadly classified into two categories: germinal and somatic. Germinal gene therapy involves introducing genes into somatic cells and an individual's germline. It not only cures the genetic disease but can also pass the altered trait to some of the individual's gametes. On the other hand, somatic gene therapy targets non-reproductive or somatic tissues to correct genetic diseases. Dysfunctional cells are removed and replaced with cloned wild-type genes. These corrected genes then provide the necessary function to alleviate disease symptoms. Typically, not all affected cells need modification, only enough to alleviate symptoms. Gene therapy products are being researched for their potential to treat diseases such as cancer, genetic disorders, and infectious diseases. Several types of gene therapy products are being explored:

1. Plasmid DNA: Circular DNA molecules engineered to carry therapeutic genes into human cells.
2. Viral Vectors: Modified viruses with their infectious capabilities removed, used as vehicles to deliver therapeutic genes into human cells.
3. Bacterial Vectors: Non-harmful bacteria serving as carriers to transport therapeutic genes into human tissues.
4. Human Gene Editing Technology: Gene editing aims to disrupt harmful genes or repair mutated ones.
5. Patient-Derived Cellular Gene Therapy Products: Cells are extracted from the patient, genetically modified (often using viral vectors), and reintroduced into the patient's body.

Gene therapy holds immense promise for the future of medicine, offering effective treatment and potential eradication of a wide range of diseases.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: